Drug Trial Radar · NCT03736369
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Dec 13, 2018
Primary completion
Aug 7, 2019
Study completion Aug 7, 2019
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
Conditions
- Erosive Esophagitis
Interventions
DWP14012 40mgDrug
DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
DWP14012 40mg placeboDrug
DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Esomeprazole 40mgDrug
Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
Esomeprazole 40mg placeboDrug
Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative healing rate of erosive esophagitis at 8week by endoscopyTime frame: at 8week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanyang University Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.